TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Ocera Therapeutics Inc (NASDAQ:OCRX) Investor Investigation Concerning Potential Securities Laws Violations Announced

  • If you purchased shares of Ocera Therapeutics Inc (NASDAQ:OCRX), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Ocera Therapeutics Inc
Security
NASDAQ: OCRX

Summary

February 9, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Ocera Therapeutics Inc (NASDAQ:OCRX) shares over potential securities laws violations by Ocera Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ocera Therapeutics Inc (NASDAQ:OCRX) concerning whether a series of statements by Ocera Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Palo Alto, CA based Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on acute and chronic orphan liver diseases. On January 30, 2017, Ocera Therapeutics Inc reported the results of its Phase 2b study of Ornithine Phenylacetate were not statistically significant in terms of the primary and secondary endpoints.

Start Monitoring Your Investments